首页> 外文期刊>chemistryselect >Identification of 1,3-(Dimethyl/Propyl)-8-Susbtituted (Cinnamic acid/Furan) Xanthine Derivatives with Anti-bronchospasmodic Activity Using in silico and in vivo Techniques
【24h】

Identification of 1,3-(Dimethyl/Propyl)-8-Susbtituted (Cinnamic acid/Furan) Xanthine Derivatives with Anti-bronchospasmodic Activity Using in silico and in vivo Techniques

机译:Identification of 1,3-(Dimethyl/Propyl)-8-Susbtituted (Cinnamic acid/Furan) Xanthine Derivatives with Anti-bronchospasmodic Activity Using in silico and in vivo Techniques

获取原文
获取原文并翻译 | 示例
           

摘要

Asthma is a chronic obstructive pulmonary disease which affects the bronchi airways and results in the inflammation of bronchioles along with the hyper-responsiveness to some direct or indirect stimuli which leads to bronchoconstriction. Substituted xanthines have provided several lead compounds for the development of antiasthmatic agents over the decades. In this present paper, a series of 42 xanthine based derivatives (17 a-g; 18 a-g; 19 a-g; 20 a-g; 28 a-g and 29 a-g) were designed and synthesized. Chemical structures were elucidated by spectroscopic methods. All target compounds were evaluated for their in silico anti-bronchospasmodic potential using PASS software. Compounds with >95 potential (18 c-f; 28 a and 29 a-g) in comparison to the standard drug were selected for in vivo bronchospasmodic activity using histamine chamber model. In silico and in vivo activity revealed that the compounds substituted with furan spacer were more active than the cinnamic acid. Substitution with propyl functionality at 1-and 3-position of xanthine moiety is also accounted for the enhanced activity of furan derivatives (29 a-g). In conclusion, the synthesized new xanthine derivatives stands out as promising anti-bronchospasmodic agents for future development.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号